Literature DB >> 18789992

Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2.

Lilian O Moreira1, Amber M Smith, Ashley A DeFreitas, Joseph E Qualls, Karim C El Kasmi, Peter J Murray.   

Abstract

The mechanisms underlying adjuvant effects are under renewed scrutiny because of the enormous implications for vaccine development. Additionally, new low-toxicity adjuvants are sought to enhance vaccine formulations. Muramyl dipeptide (MDP) is a component of the peptidoglycan polymer and was shown to be an active but low-toxicity component of complete Freund's adjuvant, a powerful adjuvant composed of mycobacteria lysates in an oil emulsion. MDP activates cells primarily via the cytosolic NLR family member Nod2 and is therefore linked to the ability of adjuvants to enhance antibody production. Accordingly, we tested the adjuvant properties of the MDP-Nod2 pathway. We found that MDP, compared to the TLR agonist lipopolysaccharide, has minimal adjuvant properties for antibody production under a variety of immunization conditions. We also observed that the oil emulsion incomplete Freund's adjuvant (IFA) supplanted the requirements for the TLR pathway independent of the antigen. Surprisingly, we observed that Nod2 was required for an optimal IgG1 and IgG2c response in the absence of exogenous TLR or NLR agonists. Collectively, our results argue that oil emulsions deserve greater attention for their immunostimulatory properties.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789992      PMCID: PMC2586078          DOI: 10.1016/j.vaccine.2008.08.038

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  44 in total

Review 1.  How do adjuvants work? Important considerations for new generation adjuvants.

Authors:  Amy S McKee; Michael W Munks; Philippa Marrack
Journal:  Immunity       Date:  2007-11       Impact factor: 31.745

2.  Bacterial cell walls, innate immunity and immunoadjuvants.

Authors:  Jack L Strominger
Journal:  Nat Immunol       Date:  2007-12       Impact factor: 25.606

Review 3.  Intracellular NOD-like receptors in host defense and disease.

Authors:  Thirumala-Devi Kanneganti; Mohamed Lamkanfi; Gabriel Núñez
Journal:  Immunity       Date:  2007-10       Impact factor: 31.745

4.  MDP-induced interleukin-1beta processing requires Nod2 and CIAS1/NALP3.

Authors:  Qilin Pan; John Mathison; Colleen Fearns; Vladimir V Kravchenko; Jean Da Silva Correia; Hal M Hoffman; Koichi S Kobayashi; John Bertin; Ethan P Grant; Anthony J Coyle; Fayyaz S Sutterwala; Yasunori Ogura; Richard A Flavell; Richard J Ulevitch
Journal:  J Leukoc Biol       Date:  2007-04-02       Impact factor: 4.962

5.  The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

Authors:  Verónica Mata-Haro; Caglar Cekic; Michael Martin; Paula M Chilton; Carolyn R Casella; Thomas C Mitchell
Journal:  Science       Date:  2007-06-15       Impact factor: 47.728

Review 6.  The genetics and immunopathogenesis of inflammatory bowel disease.

Authors:  Judy H Cho
Journal:  Nat Rev Immunol       Date:  2008-06       Impact factor: 53.106

Review 7.  MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

Authors:  D T O'Hagan; A Wack; A Podda
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

8.  A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide.

Authors:  Li-Chung Hsu; Syed R Ali; Shauna McGillivray; Ping-Hui Tseng; Sanjeev Mariathasan; Eric W Humke; Lars Eckmann; Jonathan J Powell; Victor Nizet; Vishva M Dixit; Michael Karin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-29       Impact factor: 11.205

9.  The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells.

Authors:  Anja Seubert; Elisabetta Monaci; Mariagrazia Pizza; Derek T O'Hagan; Andreas Wack
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

10.  Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells.

Authors:  Mirjam Kool; Thomas Soullié; Menno van Nimwegen; Monique A M Willart; Femke Muskens; Steffen Jung; Henk C Hoogsteden; Hamida Hammad; Bart N Lambrecht
Journal:  J Exp Med       Date:  2008-03-24       Impact factor: 14.307

View more
  15 in total

Review 1.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

2.  NLR functions beyond pathogen recognition.

Authors:  Thomas A Kufer; Philippe J Sansonetti
Journal:  Nat Immunol       Date:  2011-02       Impact factor: 25.606

3.  Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant.

Authors:  Yan Yue; Wei Xu; Sidong Xiong
Journal:  DNA Cell Biol       Date:  2011-10-11       Impact factor: 3.311

4.  The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes.

Authors:  Yun-Gi Kim; Nobuhiko Kamada; Michael H Shaw; Neil Warner; Grace Y Chen; Luigi Franchi; Gabriel Núñez
Journal:  Immunity       Date:  2011-05-12       Impact factor: 31.745

5.  Dectin-1 and NOD2 mediate cathepsin activation in zymosan-induced arthritis in mice.

Authors:  Holly L Rosenzweig; Jenna S Clowers; Gabriel Nunez; James T Rosenbaum; Michael P Davey
Journal:  Inflamm Res       Date:  2011-03-20       Impact factor: 4.575

6.  The ever-expanding function of NOD2: autophagy, viral recognition, and T cell activation.

Authors:  Michael H Shaw; Nobuhiko Kamada; Neil Warner; Yun-Gi Kim; Gabriel Nuñez
Journal:  Trends Immunol       Date:  2011-01-19       Impact factor: 16.687

7.  Activation of nucleotide oligomerization domain 2 exacerbates a murine model of proteoglycan-induced arthritis.

Authors:  H L Rosenzweig; M M Jann; T T Glant; T M Martin; S R Planck; W van Eden; P J S van Kooten; R A Flavell; K S Kobayashi; J T Rosenbaum; M P Davey
Journal:  J Leukoc Biol       Date:  2009-01-07       Impact factor: 4.962

Review 8.  Vaccine adjuvants: putting innate immunity to work.

Authors:  Robert L Coffman; Alan Sher; Robert A Seder
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

Review 9.  Developmental biology of the innate immune response: implications for neonatal and infant vaccine development.

Authors:  Victoria Jane Philbin; Ofer Levy
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

10.  T cell-intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma gondii.

Authors:  Michael H Shaw; Thornik Reimer; Carmen Sánchez-Valdepeñas; Neil Warner; Yun-Gi Kim; Manuel Fresno; Gabriel Nuñez
Journal:  Nat Immunol       Date:  2009-11-01       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.